Skip to main content
. Author manuscript; available in PMC: 2021 May 12.
Published in final edited form as: Am J Surg Pathol. 2019 Feb;43(2):187–194. doi: 10.1097/PAS.0000000000001171

Table 3:

Treatment and Follow-Up Information

Case Treatment Clinical course Outcome Follow-up (months)
1 Surgery + XRT + chemo (VDC/IE) No residual disease NED 1
2 Surgery, additional treatment pending No residual disease NED 0
3 Surgery, additional treatment pending No residual disease NED 0
4 Surgery + chemo (VDC/IE) No residual disease DWD 3
5 Surgery, additional treatment pending No residual disease NED 1
6 Surgery + XRT + chemo (doxorubicin) No residual disease NED 13
7 Surgery + XRT + chemo (carboplatin/etoposide) Persistent disease following initial therapy AWD 8
8 Surgery + XRT + chemo (VDC/IE) No residual disease NED 19
9 Surgery + XRT + chemo (initially carboplatin/paclitaxel then VDC/IE) No residual disease NED 24
10 Surgery, additional treatment pending No residual disease NED 0

VDC/IE = alternating vincristine + doxorubicin + cyclophosphamide and ifosfamide + etoposide; XRT = external beam radiation therapy; AWD = alive with disease; chemo = systemic chemotherapy; DWD = dead with disease; NED = no evidence of disease